0000899243-19-023677.txt : 20190916 0000899243-19-023677.hdr.sgml : 20190916 20190916195212 ACCESSION NUMBER: 0000899243-19-023677 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190329 FILED AS OF DATE: 20190916 DATE AS OF CHANGE: 20190916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwartz Jeffrey Lawrence CENTRAL INDEX KEY: 0001702957 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191095807 MAIL ADDRESS: STREET 1: C/O BAIN CAPITAL LIFE SCIENCES, LP STREET 2: 200 CLARENDON STRERET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-29 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001702957 Schwartz Jeffrey Lawrence C/O BAIN CAPITAL LIFE SCIENCES INVESTORS LLC, 200 CLARENDON STREET BOSTON MA 02116 1 0 1 0 Stock Option (Right to Buy) 18.00 2019-09-12 4 A 0 29983 0.00 A 2029-09-12 Common Stock 29983 29983 D Series A Convertible Preferred Stock 2019-03-29 4 A 0 40000000 A Common Stock 6078103 6078103 I See footnote Series B Convertible Preferred Stock 2019-03-29 4 A 0 6931142 A Common Stock 1053204 1053204 I See footnote This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date. On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. /s/ Jeffery Schwartz 2019-09-16